Showing results (1-10 of 179) with videos related to
Sort By:
Pageof 18
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
Flow cytometric MRD detection in selected mature B-cell malignanciesSebastian Böttcher, Matthias Ritgen, Michael KnebaHematology/Oncology Clinics of North America|April 9, 2013
The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?Sebastian Böttcher, Michael Hallek, Matthias Ritgen, et al.Journal of Immunological Methods|September 27, 2005
Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphismSebastian Böttcher, Matthias Ritgen, Monika Brüggemann, et al.Blood Reviews|January 29, 2011
Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studiesSebastian Böttcher, Matthias Ritgen, Peter DregerRheumatology International|May 5, 2006
C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosusFrank Moosig, Erika Fähndrich, Anja Knorr-Spahr, et al.Acta Haematologica|June 5, 2004
Significance of minimal residual disease in lymphoid malignanciesMonika Brüggemann, Christiane Pott, Matthias Ritgen, et al.Haematologica|May 21, 2009
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphomaInga Nagel, Takashi Akasaka, Wolfram Klapper, et al.Blood|October 7, 2006
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trialsThorsten Raff, Nicola Gökbuget, Silke Lüschen, et al.Haematologica|April 2, 2008
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsSebastian Böttcher, Matthias Ritgen, Sebastian Buske, et al.Blood|May 27, 2006
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemiaThorsten Zenz, Matthias Ritgen, Peter Dreger, et al.Pageof 18